GlassScriptPhysician profile
Neda Hashemi
NPI 1750652418
$1,419.89
in general payments reported to CMS, 2019-2025
17 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.35 · 2020: $69.12 · 2021: $12.90 · 2022: $253 · 2023: $443 · 2024: $344 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $208.35 | 2022-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $206.69 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $187.51 | 2021-2024 | Veltassa, Korsuva |
| Novo Nordisk INC | $181.96 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $121.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.92 | 2023-2024 | |
| Gilead Sciences, INC. | $96.76 | 2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $67.03 | 2022-2023 | Farxiga |
| Amgen INC. | $52.03 | 2024 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $42.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $35.10 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.06 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $19.76 | 2025 | |
| Akebia Therapeutics INC | $19.16 | 2019 | |
| Calliditas Therapeutics US INC. | $18.39 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16.69 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $14.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Hashemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.